Evidence map›Paper›PMID 39443510›Full record

ArticleScientific reports2024

Roles of miR-20a-5p in breast cancer based on the clinical and multi-omic (CAMO) cohort and in vitro studies.

Eline Sol Tylden, André Berli Delgado, Marko Lukic, Line Moi, Lill-Tove Rasmussen Busund, Mona Irene Pedersen, Ana Paola Lombardi, Karina Standahl Olsen

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Bioinformatics and biology insights · 2026
    Article
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Eline Sol TyldenDepartment of Medical Biology, Faculty of Health Sciences, UiT The Arctic University of Norway, Tromso, Norway.
André Berli DelgadoDepartment of Medical Biology, Faculty of Health Sciences, UiT The Arctic University of Norway, Tromso, Norway.
Marko LukicDepartment of Community Medicine, Faculty of Health Sciences, UiT The Arctic University of Norway, Tromso, Norway.
Line MoiDepartment of Clinical Pathology, University Hospital of North Norway, Tromso, Norway.
Lill-Tove Rasmussen BusundDepartment of Medical Biology, Faculty of Health Sciences, UiT The Arctic University of Norway, Tromso, Norway.
Mona Irene PedersenDepartment of Clinical Medicine, Faculty of Health Sciences, UiT The Arctic University of Norway, Tromso, Norway.
Ana Paola LombardiDepartment of Medical Biology, Faculty of Health Sciences, UiT The Arctic University of Norway, Tromso, Norway.
Karina Standahl OlsenDepartment of Community Medicine, Faculty of Health Sciences, UiT The Arctic University of Norway, Tromso, Norway. karina.s.olsen@uit.no.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MicroRNAs are involved in breast cancer development and progression, holding potential as biomarkers and therapeutic targets or tools. The roles of miR-20a-5p, a member of the oncogenic miR-17-92 cluster, remain poorly understood in the context of breast cancer. In this study, we elucidate the role of miR-20a-5p in breast cancer by examining its associations with breast cancer risk factors and clinicopathological features, and its functional roles in vitro. Tissue microarrays from 313 CAMO cohort breast cancer surgical specimens were constructed, in situ hybridization was performed and miR-20a-5p expression was semiquantitatively scored in tumor stromal fibroblasts, and in the cytoplasm and nuclei of cancer cells. In vitro analysis of the effect of miR-20a-5p transfection on proliferation, migration and invasion was performed in three breast cancer cell lines. High stromal miR-20a-5p was associated with higher Ki67 expression, and higher odds of relapse, compared to low expression. Compared to postmenopausal women, women who were premenopausal at diagnosis had higher odds of high stromal and cytoplasmic miR-20a-5p expression. Cytoplasmic miR-20a-5p was significantly associated with tumor grade. In tumors with high cytoplasmic miR-20a-5p expression compared to low expression, there was a tendency towards having a basal-like subtype and high Ki67. In contrast, high nuclear miR-20a-5p in cancer cells was associated with smaller tumor size and lower odds of lymph node metastasis, compared to low nuclear expression. Transfection with miR-20a-5p in breast cancer cell lines led to increased migration and invasion in vitro. While the majority of our results point towards an oncogenic role, some of our findings indicate that the associations of miR-20a-5p with breast cancer related risk factors and outcomes may vary based on tissue- and subcellular location. Larger studies are needed to validate our findings and further investigate the clinical utility of miR-20a-5p.

Indexed as

Breast NeoplasmsCell MovementCell ProliferationGene Expression Regulation, NeoplasticMicroRNAsAdultAgedBiomarkers, TumorCell Line, TumorCohort StudiesFemaleHumansMiddle AgedMultiomicsNeoplasm InvasivenessBiomarkers, TumorMicroRNAsMIRN20a microRNA, humanBiomarkerBreast cancerEpidemiologyIn situ hybridizationmicroRNAmiR-20a-5pmiRNATissue microarrayTranslational research

Identifiers

PMID39443510
PMCPMC11499649

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.